CytoDyn Company Description

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications.

The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19.

Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer.

The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

CytoDyn Inc.

Country	United States
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	14
CEO	Jacob Lalezari

Contact Details

Address: 1111 Main Street Vancouver, Washington 98660 United States
Phone	360 980 8524
Website	cytodyn.com

Stock Details

Ticker Symbol	CYDY
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	June - May
Reporting Currency	USD
ISIN Number	US23283M1018
SIC Code	2836

Key Executives

Name	Position
Dr. Jacob P. Lalezari M.D.	Chief Executive Officer
Tyler Blok	Chief Legal Officer and Corporate Secretary